The 3q29 deletion confers increased risk for neuropsychiatric phenotypes including intellectual disability, autism spectrum disorder, generalized anxiety disorder, and a >40-fold increased risk for schizophrenia. To investigate consequences of the 3q29 deletion in an experimental system, we used CRISPR/Cas9 technology to introduce a heterozygous deletion into the syntenic interval on C57BL/6 mouse chromosome 16. mRNA abundance for 20 of the 21 genes in the interval was reduced by~50%, while protein levels were reduced for only a subset of these, suggesting a compensatory mechanism. Mice harboring the deletion manifested behavioral impairments in multiple domains including social interaction, cognitive function, acoustic startle, and amphetamine sensitivity, with some sex-dependent manifestations. In addition, 3q29 deletion mice showed reduced body weight throughout development consistent with the phenotype of 3q29 deletion syndrome patients. Of the genes within the interval, DLG1 has been hypothesized as a contributor to the neuropsychiatric phenotypes. However, we show that Dlg1 +/-mice did not exhibit the behavioral deficits seen in mice harboring the full 3q29 deletion. These data demonstrate the following: the 3q29 deletion mice are a valuable experimental system that can be used to interrogate the biology of 3q29 deletion syndrome; behavioral manifestations of the 3q29 deletion may have sex-dependent effects; and mouse-specific behavior phenotypes associated with the 3q29 deletion are not solely due to haploinsufficiency of Dlg1.
Introduction
The 3q29 deletion syndrome is caused by heterozygous deletion of a 1.6 Mb interval containing 21 protein-coding genes. Individuals with the deletion are at increased risk for intellectual disability, autism spectrum disorder (ASD), generalized anxiety disorder, and schizophrenia (SZ) [1] [2] [3] [4] [5] [6] [7] . In the largest association study of copy number variation and SZ to date, the 3q29 deletion emerges as one of only eight loci achieving genome-wide significance [3] . Separate analyses have shown that the 3q29 deletion confers an exceptional risk for SZ, with an estimated effect size of >40 [8, 9] . This large effect size, coupled with the relatively low complexity of the interval and the high synteny between the human and mouse genomes, make this variant an ideal candidate for the development of a mouse experimental system. This is further aided by CRISPR/Cas9 technology facilitating engineered genomic rearrangements [10] . Collectively, the 3q29 deletion is a compelling region to study because it provides an opportunity for genetic dissection of complex neuropsychiatric phenotypes. Of the 21 genes within the interval, DLG1 and PAK2 have received attention as attractive candidates contributing to neuropsychiatric phenotypes [11] . DLG1 (a.k.a. SAP97) is a scaffolding protein that interacts with N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) type glutamate receptors [12, 13] . Suggestive evidence for association between DLG1 and neuropsychiatric phenotypes comes from sequencing studies where SZ cases are enriched for DLG1 variants compared with controls [14, 15] . An expression study of post-mortem tissue found decreased DLG1 in the prefrontal cortex in SZ patients [16] . PAK2 is implicated by its function as a regulator of cytoskeletal dynamics. Based on the current evidence for their possible involvement in neuropsychiatric phenotypes, mouse models have been created for both Dlg1 and Pak2 deficiency. A brain-specific conditional Dlg1 deletion mouse displays some sex-specific behavioral phenotypes, including subtle cognitive and motor deficits [17] . A Pak2 +/-mouse model displays autism-related behaviors and neuronal deficits [18] . Drosophila models also support involvement of dlg and pak, but behavioral and molecular phenotypes are only seen when dlg and pak are simultaneously reduced [19] .
We undertook a two-stepapproach to better understand the neuropsychiatric consequences of the 3q29 deletion and the possible contribution of DLG1 to these phenotypes. First, we created a mouse harboring a heterozygous 3q29 deletion (henceforth referred to as B6.Del16 +/Bdh1-Tfrc mice [nomenclature adapted from Mouse Genome Informatics, MGI:6241487]), and assessed gene expression, protein abundance, developmental weight trajectories, and behavioral changes associated with the deletion. Second, we used Dlg1 +/-mice to test the hypothesis that DLG1 haploinsufficiency alone is sufficient to manifest B6.Del16
+/Bdh1-Tfrc -associated phenotypes. We performed parallel analyses in both B6.Del16
+/Bdh1-Tfrc and Dlg1 +/-mice. Our results allow for integration of existing data from mouse models of other 3q29 interval genes and pave the way for careful and rigorous dissection of the genetic drivers for neuropsychiatric phenotypes within the 3q29 interval.
Materials and methods
See Supplemental Material for detailed Methods and Protocols.
Mouse strains and alleles
All mouse work was performed under the approved guidelines of the Emory University IACUC. To generate the 3q29 deletion in the mouse, two clustered regularly interspaced short palindromic repeat (CRISPR) guide RNAs (gRNAs) were designed at the syntenic loci in the mouse genome. The Emory Transgenic and Gene Targeting core injected 50 ng/μl of each gRNAs and 100 ng/μl Cas9 RNA into single-cell C57BL/6N zygotes. Embryos were cultured overnight and transferred to pseudopregnant females. 
Behavior tests
Mice were on a 12-h light/dark cycle and were given food and water ad libitum. Mice were between the ages of 16 and 20 weeks when behavioral testing commenced. All equipment was cleaned using Virkon. No method of randomization was utilized in the behavior studies.
Social interaction and Morris water maze
The three-chambered social interaction paradigm was adapted from Yang et al. [21] . The Morris water maze (MWM) was conducted using the same paradigm as Chalermpalanupap et al. [22] .
Prepulse inhibition (PPI)
The San Diego Instruments (La Jolla, CA) SR-LAB startle response system was used to perform PPI. We used a 2-day paradigm.
On day 1, we tested the ability of the mouse to startle to a series of increasing tones. On day 2, we subjected each mouse through the PPI paradigm. PPI was calculated as a percentage using the following equation: (startle-startle.PP/startle) × 100.
Amphetamine-induced locomotor activity
The assay was performed in a locomotor chamber (San Diego Instruments), which consisted of a plexiglass cage (48 × 25 × 22 cm) containing corncob bedding that rested between an apparatus containing infrared beams. The mice were given an injection of either saline or amphetamine (2.5 or 7.5 mg/kg, i.p.), and post-injection ambulations were measured for 2 h. All treatments were spread over 3 weeks and were counter balanced such that not all of the mice received the same injection in a given week. For the 7.5 mg/kg amphetamine dose, a subset of mice was video recorded between the 30 and 60 min post-injection timepoint. These videos were scored for stereotypy using the criteria as described previously [23] by an experimenter blinded to genotype. 
Additional measures

Analysis
Gene expression
Data were analyzed by two-way, repeated-measures analysis of variance (ANOVA) followed by multiple comparisons with Sidak's correction, where appropriate (i.e., only when a significant [p < 0.05] genotype effect or interaction was detected).
Behavioral tests
All behavior tests were analyzed following these parameters unless otherwise specified. Behavior was analyzed by unpaired t-test (when comparing two groups) or two-way, repeated-measures ANOVA (when comparing >2 groups), followed by multiple comparisons with Sidak's correction where appropriate (i.e., only when a significant [p < 0.05] genotype effect or interaction was detected).
Amphetamine-induced locomoter activity
All analyses performed in R [24] . Because the ambulation data were not normally distributed, the inverse normal function was used to transform the data to an approximately normal distribution. Proper transformation of the data was confirmed with the Shapiro-Wilk normality test implemented using the stats package [24] . Linear mixed-effects models with restricted maximum likelihood estimation were implemented using the lme4 package [25] . All models included subject ID and timepoint as random effects; males and females were analyzed separately. Models tested for the main effects of genotype and treatment (saline, 2.5 mg/kg amphetamine, and 7.5 mg/kg amphetamine), and for an interaction between genotype and treatment. Saline was set as the reference treatment and WT was set as the reference genotype for all analyses. p-Values were calculated using Satterthwaite's method using the lmerTest package [26] .
Acoustic startle and growth curves
Analyses for acoustic startle and growth curves were performed in R [24] . Additional details on the analyses for these tasks can be found in the supplemental materials. All data represented as mean ± SEM.
Results
Confirmation of deletion using CRISPR/Cas9
To generate mice that recapitulated the 3q29 deletion, we took advantage of several features of the syntenic region on mouse chromosome 16. The mouse and human regions are almost identical with all 21 genes present in the same order (Bex6 present in the mouse, not human). The mouse syntenic region is inverted; inversion breakpoints are identical to the SZ and ID-associated deletion breakpoints. The mouse region is also slightly smaller compared with the human region, 1.26 vs. 1.6 Mb (Fig. 1a) . To generate B6.Del16 +/Bdh1-Tfrc mice, we mimicked the 3q29 deletion breakpoints by designing CRISPR gRNAs proximal to Bdh1 and distal to Tfrc (Fig. 1b) . We performed PCR to confirm the presence of the heterozygous deletion in potential founder animals. To investigate whether the double-strand breaks during CRISPR/ Cas9 editing created additional genomic rearrangements in the region, we performed a Southern blot using a probe centromeric to the proximal breakpoint (Fig. 1b) . The radiolabelled probe hybridized to a wild-type 5.2 kb XbaI fragment on the intact, non-deleted chromosome and a 6.2 kb XbaI fragment on the deleted chromosome. Of the 23 potential founders, we identified seven (30%) animals that appeared to be properly targeted. The PCR products across the deletion were sequenced to determine the precise breakpoints for the two founders used [#127 and #131] (see Supplemental Materials).
We analyzed the expression of the 19/22 genes (Slc51a and Zdhhc19 are not expressed in brain; Bex6 is mousespecific and not present in the human interval) using forebrain tissue from both adult female and male B6. Del16 +/Bdh1-Tfrc mice. Using real-time PCR (RT-PCR), we 0% decreased gene expression in most of the genes within the 3q29 interval (with the exception of Tfrc). All genes are significantly reduced (p < 0.0001) (N = 4 wild-type, 4 mutant; 3 technical replicates per sample). d, e Protein expression analyses reveals a significant reduction in DLG1, UBXN7, PAK2, PCYT1A, WDR53, and BDH1 (***p < 0.0005, ****p < 0.0001) (N = 6 wild-type, 6 mutant ([for UBXN7 and RNF168 N = 4 wild-type, 4 mutant]. All data analyzed by two-way, repeated-measures ANOVA followed by multiple comparisons with Sidak's correction. Results represent mean ± SEM found that expression of 18/19 genes tested was 50% reduced in female (Supplemental Fig. 1a ) and male ( Fig. 1c) Fig. 2b ). We analyzed adult coronal sections with a cresyl violet stain and saw no gross differences in B6.Del16 +/Bdh1-Tfrc mice compared with their B6.WT littermates for either sex (Supplemental Fig. 2c, d ).
We assessed for any perturbation in the cortical plate using an antibody for T-box, Brain1 (TBR1). In E15.5 embryos, B6.Del16 +/Bdh1-Tfrc mice appeared to specify the cortical plate normally (Supplemental Fig. 3 ). Collectively, these data revealed altered brain size but no obvious architectural phenotypes in B6.Del16 +/Bdh1-Tfrc brain morphology.
B6.Del16
+/Bdh1-Tfrc and B6.Dlg1 +/-have normal locomotion
We assessed locomotion in B6.Del16
+/Bdh1-Tfrc and B6.
Dlg1
+/-mice using automated activity chambers by recording the number of ambulations within the chambers. We found no differences in ambulations immediately following exposure to a novel environment or over the ensuing 24 h in either female (main effect of genotype, 
B6.Del16 +/Bdh1-Tfrc male mice have social interaction deficits
Because ASD is one of the phenotypes reported in 3q29 deletion patients [2, 27] , we tested the mice for social interaction deficits using the three-chamber social approach task. We measured duration of olfactory investigation to gauge how much a given subject mouse was interacting either with the empty cup or with the cup containing the stranger mouse. As expected, both female (t 26 = 7.176, p < 0.0001) and male (t 28 = 4.018, p < 0.0005) B6.WT interacted significantly more with the stranger mouse compared with the empty cup. Female (t 24 = 3.237, p < 0.005) B6.Del16
+/Bdh1-Tfrc also showed normal sociality. By contrast, male (t 28 = 1.769, p = 0.0878) B6.Del16 +/Bdh1-Tfr mice exhibited abnormal sociality as they did not show a significant preference for the stranger mouse over the empty cup (Fig. 3a) . We then tested female and male B6.Dlg1 +/-mice to determine whether haploinsufficiency of Dlg1 led to social impairment (Fig. 3b) . We Fig. 5d-f) . We then tested for spatial memory deficits in the probe trial (Fig. 3c) 
B6.Del16 +/Bdh1-Tfrc mice display increased startle response
We examined potential differences in response to an acoustic startle and in sensorimotor gating using PPI. Female B6.Del16 +/Bdh1-Tfrc mice (Fig. 4a) (Figs. 4e-h ). These data indicate that mice harboring the 3q29 deletion have an increased response to an acoustic startle but mostly normal sensorimotor gating, whereas happloinsufficiency of Dlg1 does not alter either measure.
Amphetamine-induced locomotor activity is attenuated in B6.Del16
+/Bdh1-Tfrc mice
Chronic amphetamine use can lead to SZ symptoms, and amphetamine can exacerbate SZ symptoms in individuals that already have the disorder [28] . Because of the strong association between the 3q29 deletion and SZ, we tested amphetamine sensitivity in both B6.Del16 +/Bdh1-Tfrc and B6.
Dlg1
+/-mice. Following saline administration, neither female nor male B6.Del16 +/Bdh1-Tfrc mice displayed significant differences in ambulatory activity compared with their B6.WT littermates (main effect of genotype, p > 0.05). At both the 2.5 and 7.5 mg/kg doses of amphetamine, both female and male B6.WT mice were significantly more active compared with the respective B6.WT mice that received saline (main effect of treatment, p < 0.0001). Amphetamine-induced locomotion was attenuated in female B6.Del16 +/Bdh1-Tfrc mice following the 2.5 mg/kg (treatment × genotype interaction, p < 0.005) and 7.5 mg/kg (treatment × genotype interaction, p < 0.0001) doses compared with B6.WT littermates (Fig. 5a ). Male B6.
Del16
+/Bdh1-Tfrc mice did not show any differences in activity following the 2.5 mg/kg dose (treatment × genotype interaction, p > 0.05), but did show a reduction in activity following the 7.5 mg/kg dose (treatment × genotype interaction, p < 0.0001) of amphetamine compared with B6.WT littermates (Fig. 5b) . Because stereotypy can occlude horizontal locomotion at high doses of amphetamine, we video recorded mice from the 35-65 min post-injection and manually scored the videos for stereotypy as previously reported [23] , but did not observe any significant differences (data not shown). We then assessed amphetamine sensitivity in B6.Dlg1 +/-mice.
Neither female nor male B6.Dlg1 +/-mice displayed significant differences in ambulatory activity compared with their B6.WT littermates following administration of saline (main effect of genotype, p > 0.05). At both the 2.5 and 7.5 mg/kg dose of amphetamine, both female and male B6.WT mice were significantly more active compared with the respective B6.WT mice that received saline (main effect of treatment, p < 0.0001). Female B6.Dlg1 +/-mice did not display differences in activity at the 2.5 mg/kg (treatment × genotype interaction, p > 0.05) or 7.5 mg/kg (treatment × genotype interaction, p > 0.05) amphetamine doses compared with their B6.WT littermates (Fig. 5c) . Male B6.Dlg1 +/-mice showed a small but significant increase in ambulatory activity following administration of 2.5 mg/kg amphetamine (treatment × genotype interaction, p < 0.001), but no significant PPI data analyzed by two-way, repeated-measures ANOVA followed by multiple comparisons. Results represent the mean ± SEM (*p < 0.05) changes in activity following the 7.5 mg/kg dose (treatment × genotype interaction, p > 0.05) compared with B6.WT littermates (Fig. 5d) . Taken together, these data show that B6. Del16 +/Bdh1-Tfrc mice display attenuated amphetamine-induced locomotor activity that is not solely due to haploinsufficiency of Dlg1.
Anxiety-like behavior and associative memory are not changed in B6.Del16 +/Bdh1-Tfrc and B6.Dlg1
We assessed performance in several tests for anxiety-like behavior (elevated plus maze, open field, marble burying) and did not observe any differences in the respective tasks (p > 0.05) in B6.Del16 +/Bdh1-Tfrc or B6.Dlg1 +/-mice compared with B6.WT littermates (Supplemental Fig. 7) [statistics located in respective figure legend].
We assessed associative learning and memory using context and cued fear conditioning. During training, female B6. Del16 +/Bdh1-Tfrc mice did not show any genotype-wide differences compared with B6.WT littermates, but did show a significant interaction (main effect of time × genotype, F 21, 630 , p < 0.0005). Sidak's post-hoc analysis revealed female B6. Del16 +/Bdh1-Tfrc mice froze significantly more at the 300 (p < 0.01), 360 (p < 0.05), and 380 (p < 0.0001) second time points compared with B6.WT littermates (Supplemental Fig. 8a ). This result is consistent with the increased acoustic startle +/Bdh1-Tfrc mice displayed no significant differences in ambulatory activity compared with B6.WT littermates after saline administration (main effect of genotype, p > 0.05). Female B6.WT mice displayed increased activity when given a 2.5 mg/kg or a 7.5 mg/kg dose of amphetamine compared with B6.WT littermates that received saline (main effect of treatment, p < 0.0001). Female B6.Del16
+/Bdh1-Tfrc mice displayed attenuated activity following a 2.5 mg/kg dose (treatment × genotype interaction, **p < 0.005) and a 7.5 mg/kg dose (treatment × genotype interaction, ****p < 0.0001) of amphetamine compared with B6.WT littermates. b Male B6.Del16 +/Bdh1-Tfrc mice displayed no significant differences in ambulatory activity compared with B6.WT littermates after saline administration (main effect of genotype, p > 0.05). Male B6.WT mice displayed increased activity when given a 2.5 mg/kg or a 7.5 mg/kg dose of amphetamine compared with B6.WT littermates that received saline (main effect of treatment, p < 0.0001). Male B6.Del16 +/Bdh1-Tfrc mice displayed no significant changes in activity following a 2.5 mg/kg dose (treatment × genotype interaction, p > 0.05), but did show attenuated activity following a 7.5 mg/kg dose (treatment × genotype interaction, ****p < 0.0001) of amphetamine compared with B6.WT littermates. c Female B6.Dlg1 +/-mice displayed no significant differences in ambulatory activity compared with B6.WT littermates after saline administration (main effect of genotype, p > 0.05). Female B6.WT mice displayed increased activity when given a 2.5 mg/kg or a 7.5 mg/kg dose of amphetamine compared with B6.WT littermates that received saline (main effect of treatment, p < 0.0001). Female B6. Dlg1 +/-mice displayed no changes in activity after a 2.5 mg/kg dose (treatment × genotype interaction, p > 0.05) or a 7.5 mg/kg dose (treatment × genotype interaction, p > 0.05) compared with B6.WT littermates. d Male B6.Dlg1 +/-mice displayed no significant differences in ambulatory activity compared with B6.WT littermates after saline administration (main effect of genotype, p > 0.05). Male B6.WT mice displayed increased activity when given a 2.5 mg/kg or a 7.5 mg/kg dose of amphetamine compared with B6.WT littermates that received saline (main effect of treatment, p < 0.0001). Male B6.Dlg1 +/-mice displayed increased activity following a 2.5 mg/kg dose (treatment × genotype interaction, ***p < 0.001), but not a 7.5 mg/kg dose (treatment × genotype interaction, p > 0.05) of amphetamine compared with B6.WT littermates. All data were analyzed as outlined in methods. Results represent mean ± SEM (*p < 0.05). B6. Fig. 8b, c) Fig. 8d-f Fig. 9e, f) . Collectively, we did not observe fear-dependent memory impairments in B6.Del16 +/Bdh1-Tfrc mice.
Discussion
Here we report engineering a 3q29 deletion mouse model, and show it displays growth and behavioral deficits relevant to human 3q29 deletion syndrome phenotypes. Both female and male B6.Del16 +/Bdh1-Tfrc mice weigh significantly less than their B6.WT littermates, over the course of postnatal development and into adulthood, consistent with a prior study of humans with 3q29 deletion syndrome [2] . In contrast, female but not male B6.Dlg1 +/-mice weigh significantly less than their B6.WT littermates suggesting that haploinsufficiency of Dlg1 may be a partial contributor to the growth phenotype in female B6.Del16
+/Bdh1-Tfrc mice. We found multiple behavioral differences in B6. Del16 +/Bdh1-Tfrc mice that are endophenotypes of the neuropsychiatric disorders observed in 3q29 deletion study subjects [2, 9, 12] . Male B6.Del16 +/Bdh1-Tfrc mice demonstrated social and cognitive impairment in the threechambered social interaction and MWM tests, respectively, consistent with ASD and intellectual disability seen in humans with 3q29 deletion syndrome. Female B6. Del16 +/Bdh1-Tfrc mice showed an increased startle response consistent with reported hypersensitivity to acoustic stimuli in ASD patients [29] . Female and male B6.Del16
+/Bdh1-Tfrc mice showed attenuated sensitivity to amphetamine-induced locomotor activity at a high dose of drug, suggesting perturbations in the dopaminergic system and demonstrating a shared behavior phenotype. Disruptions in dopamine signaling have been shown to confer risk for both ASD and SZ [30, 31] . We also demonstrated that B6.Dlg1 +/-mice did not share any of the behavioral phenotypes that are observed in B6.Del16 +/Bdh1-Tfrc mice. These data indicate that B6.
Del16
+/Bdh1-Tfrc mice display 3q29-related phenotypes that are not due solely to haploinsufficiency of Dlg1.
The finding that the B6.Del16 +/Bdh1-Tfrc mouse recapitulates aspects of 3q29 deletion at the genetic and phenotypic levels strongly suggests that the genetic drivers are within the 3q29 interval. The major difference between the mouse and human intervals is that the syntenic regions are inverted. This inversion occurred within the great ape lineage, as chimpanzees and humans have the same (derived) orientation of the region, but rhesus macaques have the inverted (ancestral) orientation that is present in mice. A copy number neutral inversion of the region has been identified in humans, with no apparent phenotype [32] . This implies that the critical event for the phenotype is the deletion itself, not a misregulation of a gene outside the deletion region. The fact that all 21 genes in the human 3q29 region are conserved in mouse and single gene mutations of each are being analyzed on the same genetic background through the International Mouse Phenotyping Consortium argues the region is ripe for genetic dissection. The B6.Del16
+/Bdh1-Tfrc mouse provides an entry point for such genetic dissection and ultimately, understanding of the circuitry and molecular mechanisms underlying these phenotypes. Towards this goal, the behavioral deficits provide clues to which brain regions may be most affected by the 3q29 deletion: the MWM is a hippocampal-dependent task [33, 34] , social interaction is a striatum-dependent task [35] , and startle response is dependent on the caudal pontine reticular nucleus [36] . Thus, the observed deficits in B6. Del16 +/Bdh1-Tfrc mice that we observed in the MWM are potential disruptions in these respective brain regions. Such relationships provide a starting point for evaluating the circuitry that may be disrupted in the B6.Del16 +/Bdh1-Tfrc mice, which may also be relevant for human 3q29 deletion patients. While this current work focused on specific symptoms exhibited by 3q29 deletion patients, the mice have the potential to inform other 3q29 deletion phenotypes. The ongoing Emory 3q29 Project (http://genome.emory.edu/3q29/) has an active component where human study subjects participate in a comprehensive set of clinical evaluations [37] . Phenotypic data from the B6.Del16 +/Bdh1-Tfrc mice can inform human phenotyping protocols and downstream analyses. For example, we observed sex-specific differences in our behavioral assertation of the B6.Del16 +/Bdh1-Tfrc mice but only limited patient phenotypes have been evaluated in a sex-specific way. We suspect that the sex-based differences we observed in the mice are due to intrinsic biological differences between females and males. Certainly, sex-specific differences are exhibited in other neuropsychiatric diseases, notably ASD where four times as many males as females are affected [38] [39] [40] . Though purely speculative in relation to the 3q29 deletion, our behavior data demonstrates differences between B6.Del16 +/Bdh1-Tfrc females and male mice, which could be due to sex-specific molecular phenotypes. Although the formal possibility exists that the variability in estrous stage contributed to the sex differences we observed, we think this is an unlikely explanation. The females were group-housed, minimizing any such variation. Furthermore, male mice display as much variability in behavioral assays as female mice without estrous control [41] . These sexspecific differences are significant as they underscore the importance of studying both sexes in mice and humans. Our Dlg1 +/-analyses argue that haploinsufficiency of Dlg1 alone is not sufficient to explain the phenotypes associated with the B6.Del16 +/Bdh1-Tfrc mice, and points to either a different gene or a combination of genes within the interval that may or may not include Dlg1 driving phenotypes. These data highlight the power of our approach. Recently, a neuron-specific deletion of Dlg1 was reported to produce cognitive deficits in the males and motor learning deficits in the females [17] . While this work identified differentially expressed genes in the hippocampus, the transcriptional profile is likely much different when only one copy of DLG1 is deleted as in 3q29 deletion patients. The tissue-specific complete deletion of Dlg1 also focuses on the role in neurons, but other cell types, such as glia, may contribute to 3q29 deletion associated phenotypes. One potential modifier of DLG1 is PAK2. In Drosophila, single pak-/+ or dlg-/+ mutants showed no phenotype but compound pak-/+; dlg-/+ flies showed decreased number of neuromuscular boutons indicating a genetic interaction [19] . Although this interaction remains unexamined in mouse, male Pak2 +/-mice are impaired on several social tasks including the three-chamber social interaction protocol used in the present study [18] . Diminished Pak2 likely contributes to the social impairment we observed in the B6. Del16 +/Bdh1-Tfrc male mice.
Several behavioral assays performed in the present study did not reveal phenotypes in the B6.Del16
+/Bdh1-Tfrc mice.
Based on the known manifestations of 3q29 deletion in humans, we hypothesized that some of these phenotypes would be apparent, such as anxiety [2] . It is possible that more complex human life experiences such as early life stress contribute to these phenotypes. Alternatively, our mouse studies were conducted on the C57BL/6N inbred strain, which may have obscured modifying genetic elements. Thus, examining the Del16 +/Bdh1-Tfrc on different genetic backgrounds could reveal additional impairments. It is also entirely possible that the distinctions in phenotype reflect fundamentally different biology between mice and humans. Nonetheless, the B6.Del16 +/Bdh1-Tfrc mouse will be an important tool to move forward and explore these issues and to systematically generate sub-deletions to genetically dissect the regions of the 3q29 interval driving the observed phenotypes. This 3q29 deletion mouse provides an excellent tool to continue the quest of unraveling the puzzle of neuropsychiatric disorders.
